Bronchiolitis is a recurring lung illness that affects new-borns and small children. It causes inflammation and obstruction in the lungs’ tiny airways (bronchioles). It can make you wheeze, cough and have trouble breathing. It occurs when the bronchioles, or small breathing tubes in the lungs, get inflamed. As a result of the mucus clogging the tubes, there isn’t enough room for air to get in and out of the lungs. The respiratory syncytial virus (RSV), influenza (flu) viruses and rhinovirus are the most common causes of bronchiolitis.
Data Bridge Market Research analyses that the bronchiolitis drugs market was valued at USD 58.62 million in 2021 and is expected to reach USD 83.37 million by 2029, registering a CAGR of 4.50% during the forecast period of 2022 to 2029. The market report curated by the Data Bridge Market Research team includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Some of the major players operating in the bronchiolitis drugs market are:
- Pfizer Inc. (US)
- GlaxoSmithKline plc (UK)
- Novartis AG (Switzerland)
- Mylan N.V. (US)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Sanofi (France)
- Boehringer Ingelheim International GmbH. (Germany)
- AstraZeneca (UK)
- Johnson & Johnson Private Limited (US)
- Merck & Co., Inc. (US)
- F. Hoffmann-La Roche Ltd. (Switzerland)
- Bristol-Myers Squibb Company (US)
- Eli Lilly and Company (US)
- Allergan (Ireland)
- Abbott (US)
- LEO Pharma A/S (Denmark)
- Sun Pharmaceutical Industries Ltd. (India)
- Aurobindo Pharma (India)
- Lupin (India)
- Hikma Pharmaceuticals PLC (UK)
- Amneal Pharmaceuticals LLC. (US)
- Zydus Cadila (India)
- Akorn, Incorporated (US)
Bronchiolitis drug market dynamics
- Increased prevalence of respiratory syncytial virus (RSV) infection
The increasing prevalence of respiratory syncytial virus (RSV) infection is a major factor driving the growth rate of the bronchiolitis drug market. According to the Centers for Disease Control and Prevention (CDC), the respiratory syncytial virus (RSV) causes the hospitalization of 1,32,000-172,000 children over five years and the death of 14,000 adults over 65 years of age In the U.S. United alone every year. Developing countries account for almost all RSV-related mortality in children under five years of age.Since respiratory syncytial virus (RSV) infections show clinical signs similar to other respiratory diseases, there is a growing demand for rapid, specific and sensitive diagnostic procedures.
- High prevalence rate of smoking
The increase in the prevalence rate of smoking will act as an important factor resulting in the expansion of the growth rate of the market. Smoking is one of the causal factors that increases the risk of viral bronchiolitis by increasing respiratory problems, and thus will further reduce the growth rate of the bronchiolitis medicine market.
In addition, increased initiatives by public and private organizations to raise awareness and increased spending on healthcare will expand the market for bronchiolitis medications. In addition, the changing lifestyle of people and the increasing number of cases of heart disease and chronic lung disorders will drive the expansion of the bronchiolitis medicine market. Along with this, the rising incidence of respiratory diseases and the rising number of geriatric people will enhance the growth rate of the market.
- Increased number of research and development activities
Furthermore, the growth of the market is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the growth of the bronchiolitis drugs market. Along with this, the increase in drug approvals and launches will further drive the growth rate of the market.
Moreover, increased investments for the development of advanced technologies and increase in the number of emerging markets will provide further beneficial opportunities for the growth of the Bronchiolitis Drugs market during the forecast period.
For More Information About Market Analysis, Browse Research Report Summary @: www.databridgemarketresearch.com/reports/global-bronchiolitis-drugs-market
The bronchiolitis drugs market is segmented on the basis of type, treatment, dosage form, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
- Antiviral drugs
- Aerosolized ribavirin
- Oxygen Therapy
- Intravenous Fluids
- Viral Bronchiolitis
- Bronchiolitis Obliterans
Route of Administration
- Specialty Clinics
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
MV130 (Bactek) is being developed by Inmunotek for the treatment of Bronchiolitis. In addition to eliciting specific T cell immunity against the germs present in the preparation, MV130 also demonstrates an increased T cell response to an unrelated flu antigen. TLR and NLR signaling pathways are triggered on DCs, resulting in the release of trained immunity markers.
Bronchiolitis Drugs Market Regional Analysis/Insights
The bronchiolitis drugs market is analysed and market size insights and trends are provided by country, type, treatment, dosage form, route of administration, end-users and distribution channel as referenced above. The countries covered in the bronchiolitis drugs market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
North America dominates the bronchiolitis drugs market in terms of market share and market revenue and will continue to flourish its dominance during the forecast period. This is due to the presence of major key players and rising healthcare expenditure will further propel the market’s growth rate in this region. Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to surging prevalence of inflammatory respiratory diseases in this region. Also, development of healthcare infrastructure will further propel the market’s growth rate in this region.
Explore Complete TOC At :- www.databridgemarketresearch.com/toc/?dbmr=global-bronchiolitis-drugs-market
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter’s five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Top Healthcare Report Links:
About Data Bridge Market Research:
An absolute way to forecast what future holds is to comprehend the trend today! Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavours to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process. Data Bridge is an aftermath of sheer wisdom and experience which was formulated and framed in the year 2015 in Pune.
Data Bridge Market Research has over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.
Data Bridge Market Research
US: +1 888 387 2818
UK: +44 208 089 1725
Hong Kong: +852 8192 7475
Email:- [email protected]